Avalyn Pharma Inc. (NASDAQ:AVLN - Get Free Report) insider Howard Lazarus sold 13,300 shares of the business's stock in a transaction on Tuesday, November 17th. The shares were sold at an average price of $27.90, for a total transaction of $371,070.00. Following the completion of the transaction, the insider directly owned 13,300 shares of the company's stock, valued at $371,070. This trade represents a 50.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Avalyn Pharma Stock Up 3.6%
Shares of AVLN traded up $1.01 during trading hours on Thursday, reaching $28.70. The stock had a trading volume of 437,291 shares, compared to its average volume of 344,822. The company has a market cap of $1.28 billion and a P/E ratio of -1.26. Avalyn Pharma Inc. has a 52 week low of $22.24 and a 52 week high of $40.17. The company has a current ratio of 25.76, a quick ratio of 25.76 and a debt-to-equity ratio of 0.04. The company's 50-day moving average is $28.15.
Avalyn Pharma (NASDAQ:AVLN - Get Free Report) last posted its earnings results on Thursday, November 12th. The company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.64) by ($0.03). As a group, equities analysts expect that Avalyn Pharma Inc. will post -3.87 earnings per share for the current year.
Analyst Upgrades and Downgrades
A number of research analysts have weighed in on AVLN shares. Raymond James Financial started coverage on shares of Avalyn Pharma in a research note on Friday, October 2nd. They issued an "outperform" rating and a $60.00 price target on the stock. Weiss Ratings reiterated a "sell (d+)" rating on shares of Avalyn Pharma in a report on Wednesday, November 11th. Wall Street Zen raised shares of Avalyn Pharma from a "sell" rating to a "hold" rating in a research report on Saturday, November 14th. Finally, Morgan Stanley dropped their price objective on shares of Avalyn Pharma from $57.00 to $53.00 and set an "overweight" rating on the stock in a report on Monday. Two analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $59.20.
Read Our Latest Stock Report on AVLN
Institutional Trading of Avalyn Pharma
A number of institutional investors have recently modified their holdings of AVLN. Montanova Capital LLC acquired a new stake in Avalyn Pharma in the 2nd quarter valued at approximately $82,402,000. Braidwell LP bought a new stake in Avalyn Pharma in the 2nd quarter valued at approximately $26,382,000. Soleus Capital Management L.P. boosted its position in Avalyn Pharma by 143.2% during the 3rd quarter. Soleus Capital Management L.P. now owns 1,019,000 shares of the company's stock worth $29,031,000 after acquiring an additional 600,000 shares during the last quarter. State Street Corp acquired a new position in Avalyn Pharma during the 2nd quarter worth approximately $10,501,000. Finally, Bank of New York Mellon Corp acquired a new position in Avalyn Pharma during the 2nd quarter worth approximately $1,321,000.
Avalyn Pharma Company Profile
(
Get Free Report)
Avalyn Pharma is a clinical-stage biopharmaceutical company developing inhaled treatments for pulmonary fibrosis, including idiopathic pulmonary fibrosis and other progressive fibrotic lung diseases. Its approach is designed to deliver medicine directly to the lungs. The company's pipeline includes AP01, an investigational inhaled formulation of pirfenidone, and AP02, an investigational inhaled formulation of nintedanib. Both medicines are based on drugs used in oral form for pulmonary fibrosis, but Avalyn's inhaled candidates are being studied as potential alternatives to oral treatment.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Avalyn Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Avalyn Pharma wasn't on the list.
While Avalyn Pharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.